



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Hwu et al.

RECEIVED

SEP 13 2002

TECH CENTER 1600/2900

Application No. 09/803,578

Art Unit: 6841

Filed: March 9, 2001

Examiner: Michael C. Wilson

For: ACTIVATED DUAL SPECIFICITY
LYMPHOCYTES AND THEIR
METHODS OF USE

AMENDMENT TO SPECIFICATION
MADE IN RESPONSE TO OFFICE ACTION DATED July 8, 2002

(Insertions are indicated with underlining)

Amendments to paragraph [0047]:

[0047] In one preferred embodiment, the tumor associated antigens recognized by the receptors of this invention are melanoma antigens. By way of example, melanoma specific T-cell receptors may recognize melanoma antigens in the context of HLA-A2.1 or HLA-A1. Examples of melanoma antigens which are recognized by the chimeric receptors include, but are not limited to, MART-1, or peptides thereof or gp-100 or peptides thereof. In a preferred embodiment the chimeric receptor recognizes or binds to the MART-1 peptide, in particular epitopes M9-1 (TTAEEAAGI) (SEQ ID NO:1), M9-2 (AAGIGILTV) (SEQ ID NO:2), M10-3 (EAAGIGILTV) (SEQ ID NO 3), and M10-4 (AAGIGILTVI) (SEQ ID NO: 4) (shown in single letter amino acid code) or gp-100 peptide epitopes.